BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Sanofi, Formation Bio, and OpenAI Partner to Innovate Drug Development with AI

by Roman Kasianov   •   May 22, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Sanofi, Formation Bio, and OpenAI have announced a pioneering collaboration aimed at accelerating drug development using artificial intelligence (AI). This partnership will combine proprietary data, advanced software, and specialized AI models to create tailored solutions for various stages of the drug development lifecycle.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Sanofi, a global healthcare company dedicated to advancing medicine through scientific innovation, plans to utilize this collaboration to enhance its AI capabilities, aligning with its stated goal to become the first biopharma company extensively powered by AI. The company's proprietary data will be instrumental in developing these AI models, furthering its mission to innovate drug development processes.

Paul Hudson, CEO of Sanofi, emphasized the significance of this collaboration, stating:

“This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next-generation, first-of-its-kind AI model customizations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments.”

OpenAI, renowned for its AI research, will contribute its leading-edge AI technology, including fine-tuning models and providing deep AI expertise and resources.

See also: 11 Publicly Traded Biotechs Utilizing AI-based Research Platforms

Formation Bio, known for its AI and tech-driven approach to drug development, is said to bring extensive engineering resources and a robust tech-driven development platform to the table. The company aims to design, develop, and deploy AI technologies across all aspects of the pharmaceutical lifecycle. Founded in 2016 as TrialSpark Inc., Formation Bio focuses on overcoming the bottlenecks in drug development by leveraging AI to accelerate clinical trials and other development processes. By partnering, acquiring, or in-licensing drugs from various entities, Formation Bio aims to expedite the journey from clinical proof of concept to bringing new medicines to patients.

Formation Bio

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.